The change in serum TNF-α and sFas among primary liver cancer patients before and after Double intra-arterial infusion of anti-cancer agent

Objective To study the clinical significance of change in serum TNF-αand sFas among primary liver cancer patients before and after Double intra-arterial infusion of anti-cancer agent.Methods A total of 75 patients with primary liver cancer were treated with TACE (35 patients) , and TACE Combined with Splenic Arterial Set-catheter Infusion (45 patients) .In addition, 30 patients were included in the study as a normal control group.The patients serum TNFαand sFas were determined before and two weeks after therapy and all the patients were evaluated for the effect of treatment simultaneously.Results Serum TNF-α and sFas levels of primary liver cancer patients were higher than the normal control group (P < 0.01) .Serum TNF-α and sFas levels in patients treated with TACE and Double intra-arterial infusion of anti-cancer agents were lower than the control group (P < 0.01) .The serum TNF-α and sFas levels of patients treated with Double intra-arterial infusion anti-cancer agent were lower than the TACE treatment group (P < 0.05) .Double intra-arterial infusion anti-cancer agent therapy had shown a significant effect on serum TNF-α and sFas's levels of the treated patients than the patients that were not treated (P < 0.01) .Conclusion Patients that were treated with Double intraarterial infusion of anti-cancer agent were shown a significant decrease in serum TNF-α and sFas measurement.Therefore, these parameters can be used to estimate disease prognosis.